Do the results of FIBRONEER-ILD change your approach to antifibrotic treatment in patients with sarcoidosis related PPF?

It changes my thinking somewhat, but I would be careful not to overinterpret the sarcoidosis results. FIBRONEER-ILD supports the broader concept that once different non-IPF ILDs develop a progressive fibrotic phenotype, targeting fibrosis may be beneficial regardless of the original diagnostic label...

According to the FIBRONEER-PPF data, no sarcoidosis-specific outcomes have been reported, and one can only infer that the sarcoidosis-related PPF subpopulation has tracked similarly to the other ILD subtypes, which is a big assumption. It is important to remember that in the INBUILD study, which exa...

There is limited data regarding antifibrotics in sarcoidosis-associated pulmonary fibrosis. The INBUILD study of nintedanib in progressive pulmonary fibrosis did include a small group of patients with fibrotic sarcoidosis. The overall results did show a slowing in FVC loss, but specific information ...